Bria-Pros+ Activates Multiple Immune Cell Types Figure 1 shows that Bria-Pros+ activates a range of immune cells in a modified...
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing...
SPARKS, NV / ACCESSWIRE / January 31, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased...
Press Release High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team...
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ACARIZAX® (house dust mite...
TURKU, Finland and BOSTON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage...
Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine...
SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with...
BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to...
Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T...
Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New...
SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to...
A post hoc analysis found the efficacy of camrelizumab plus rivoceranib was superior to sorafenib regardless of baseline liver function...
AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker...
Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy...
Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing...
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose...
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040,...
Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Market opportunity estimated to be greater than US$1...
Financing advances development of Prota's peanut allergy remission therapy in preparation for a Phase 3 clinical trialMELBOURNE, AUSTRALIA / ACCESSWIRE...